Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03762018
Title BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma (BEAT-meso)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors European Thoracic Oncology Platform
Indications

malignant pleural mesothelioma

Therapies

Bevacizumab + Carboplatin + Pemetrexed Disodium

Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries


No variant requirements are available.